Monopar Therapeutics公司的背景是什麼？

詳細公司背景可參考: [https://www.monopartx.com](https://www.monopartx.com)。

Monopar Therapeutics

MNPR

2.390

0.000

0.00%

概況消息

最少15分鐘延遲，股票資訊由第三方資訊供應商提供

・Monopar Therapeutics - 延遲價格・最後更新於 06/07 6:58

最高位: 2.390
最低位: 2.390
開市價: --
前收市價: 2.390
成交量(千): 0.00
成交額(百萬): 0.00
買入: 2.150
賣出: 2.420
每手股數: --
市值(百萬): 30.16
市盈率: --
息率: --
差價: --
52週高低: 6.980 - 1.702

所有資料不保證絕對正確、完整、或實時，僅作為參考使用。投資涉及風險，過往業績並不代表將來表現，作任何投資決定或交易前，閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱: Monopar Therapeutics
證券代碼: MNPR.US
所屬板塊: Biotechnology
公司業務: Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
發行量: 12604514
公司總部: 1000 Skokie Boulevard, Suite 350
公司網址: https://www.monopartx.com
公司電郵: info@monopartherapeutics.com
公司電話: +1 847 388-0349

關於

Monopar Therapeutics(MNPR.US)所屬的行業板塊為Biotechnology。

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

詳細公司背景可參考: https://www.monopartx.com。

快訊

資訊

虛擬市場

Monopar Therapeutics

企業資料

最新發佈

關於